Bio-Rad Laboratories (BIO) Short term Debt (2009 - 2010)
Bio-Rad Laboratories (BIO) reported Short term Debt of $731.1 million for Q4 2010, down 0.92% year-over-year from $737.9 million in Q4 2009, and down 0.92% on a QoQ basis from $737.9 million in Q4 2009.
Bio-Rad Laboratories (BIO) has 2 years of Short term Debt data on file, last reported at $731.1 million in Q4 2010.
- Quarterly Short term Debt fell 0.92% year-over-year to $731.1 million in Q4 2010, while the trailing twelve-month figure through Dec 2010 was $731.1 million (down 0.92% YoY) and the FY2010 annual result came in at $731.1 million, down 0.92% from the prior year.
- Short term Debt fell to $731.1 million in Q4 2010 per BIO's latest filing, from $737.9 million in the prior quarter.
- Across five years, Short term Debt topped out at $737.9 million in Q4 2009 and bottomed at $731.1 million in Q4 2010.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Bio-Rad Laboratories | 8.23 Bn | 6.66 Bn | 309.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2010 | 731.10 Mn |
| Dec 31, 2009 | 737.92 Mn |